In this column, KFF’s President and CEO Drew Altman explores the nation’s twin health cost crises of affordability, especially for people who are sick and need a lot of health care, and national health spending, and why the solutions often work at cros…
In September 2023, the Centers for Medicare and Medicaid Services (CMS) announced a new opportunity for states to leverage federal funding on health care: the Advancing All-Payer Health Equity Approaches and Development (AHEAD) model. With this model, …
In September 2023, the Centers for Medicare and Medicaid Services (CMS) announced a new opportunity for states to leverage federal funding on health care: the Advancing All-Payer Health Equity Approaches and Development (AHEAD) model. With this model, …
This slideshow looks at past, present and future trends in prescription drug spending with a focus on the role of specialty drugs.
As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in t…
This brief explains the role and implications of cross-market mergers between hospitals and health systems that operate in different regions and describes the approaches that government antitrust agencies have taken in reviewing these types of transact…
This brief explains the role of federal and state antitrust agencies in challenging anticompetitive practices among hospitals and other health care providers, including the legal authority of federal and state agencies, the role that they play in enfor…
Prices for medical services typically rise more quickly than the broader economy, but the reverse has been true recently as general inflation rose rapidly. This analysis finds that overall prices grew by 6% in February 2023 from the previous year, whil…
This analysis finds that privately insured adults who were treated for depression and/or anxiety in 2021 spent almost twice as much on annual out-of-pocket costs compared to enrollees who were not treated for a mental health diagnosis.
This analysis finds that privately insured adults who were treated for depression and/or anxiety in 2021 spent almost twice as much on annual out-of-pocket costs compared to enrollees who were not treated for a mental health diagnosis.
